OSI-7904L free acid

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584309

CAS#: 139987-54-5 (free acid)

Description: OSI-7904L, also known as 1843U89, is a folate-based thymidylate synthase inhibitor with antimalarial and antitumor properties.

Chemical Structure

OSI-7904L free acid
CAS# 139987-54-5 (free acid)

Theoretical Analysis

MedKoo Cat#: 584309
Name: OSI-7904L free acid
CAS#: 139987-54-5 (free acid)
Chemical Formula: C27H24N4O6
Exact Mass: 500.1696
Molecular Weight: 500.511
Elemental Analysis: C, 64.79; H, 4.83; N, 11.19; O, 19.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 2197232-28-1 (racemic)   139987-54-5 (free acid)    

Synonym: OSI-7904L; OSI7904L; OSI 7904L; OSI 7904; OSI7904; OSI-7904; 1843U89; BW 1843U89; BW-1843U89; BW1843U89; GW 1843; GW1843; GW-1843; GW 1843U89; OSI 7904L;

IUPAC/Chemical Name: Pentanedioic acid, 2-(5-(((1,2-dihydro-3-methyl-1-oxobenzo(f)quinazolin-9-yl)methyl)amino)-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, (S)-


InChi Code: InChI=1S/C27H24N4O6/c1-14-29-21-7-4-16-3-2-15(10-20(16)24(21)25(34)30-14)12-28-18-5-6-19-17(11-18)13-31(26(19)35)22(27(36)37)8-9-23(32)33/h2-7,10-11,22,28H,8-9,12-13H2,1H3,(H,32,33)(H,36,37)(H,29,30,34)/t22-/m0/s1

SMILES Code: O=C(O)[C@@H](N(CC1=C2C=CC(NCC3=CC=C4C(C5=C(N=C(C)NC5=O)C=C4)=C3)=C1)C2=O)CCC(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 500.511 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Smith GK, Amyx H, Boytos CM, Duch DS, Ferone R, Wilson HR. Enhanced antitumor activity for the thymidylate synthase inhibitor 1843U89 through decreased host toxicity with oral folic acid. Cancer Res. 1995 Dec 15;55(24):6117-25. PubMed PMID: 8521402.

2: Hanlon MH, Ferone R. In vitro uptake, anabolism, and cellular retention of 1843U89 and other benzoquinazoline inhibitors of thymidylate synthase. Cancer Res. 1996 Jul 15;56(14):3301-6. PubMed PMID: 8764125.

3: Wilson RH. Novel therapeutic developments other than EGFR and VEGF inhibition in colorectal cancer. Oncologist. 2006 Oct;11(9):1018-24. Review. PubMed PMID: 17030644.

4: Li WW, Tong WP, Bertino JR. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate. Clin Cancer Res. 1995 Jun;1(6):631-6. PubMed PMID: 9816025.

5: Schwartz G, Johnson TR, Goetz A, Burris H, Smetzer L, Lampkin T, Sailstad J, Hohneker JA, Von Hoff DD, Rowinsky EK. A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies. Clin Cancer Res. 2001 Jul;7(7):1901-11. PubMed PMID: 11448903.

6: Clamp AR, Schöffski P, Valle JW, Wilson RH, Marreaud S, Govaerts AS, Debois M, Lacombe D, Twelves C, Chick J, Jayson GC; EORTC New Drug Development Group. A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemother Pharmacol. 2008 Apr;61(4):579-85. Epub 2007 May 23. PubMed PMID: 17520255.

7: Desjardins J, Emerson DL, Colagiovanni DB, Abbott E, Brown EN, Drolet DW. Pharmacokinetics, safety, and efficacy of a liposome encapsulated thymidylate synthase inhibitor, OSI-7904L [(S)-2-[5-[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino-1-oxo- 2-isoindolynl]-glutaric acid] in mice. J Pharmacol Exp Ther. 2004 Jun;309(3):894-902. Epub 2004 Feb 24. PubMed PMID: 14982966.

8: Wong SC, Proefke SA, Bhushan A, Matherly LH. Isolation of human cDNAs that restore methotrexate sensitivity and reduced folate carrier activity in methotrexate transport-defective Chinese hamster ovary cells. J Biol Chem. 1995 Jul 21;270(29):17468-75. PubMed PMID: 7615551.

9: Jiang L, Lee PC, White J, Rathod PK. Potent and selective activity of a combination of thymidine and 1843U89, a folate-based thymidylate synthase inhibitor, against Plasmodium falciparum. Antimicrob Agents Chemother. 2000 Apr;44(4):1047-50. PubMed PMID: 10722510; PubMed Central PMCID: PMC89811.

10: Pang CK, Hunter JH, Gujjar R, Podutoori R, Bowman J, Mudeppa DG, Rathod PK. Catalytic and ligand-binding characteristics of Plasmodium falciparum serine hydroxymethyltransferase. Mol Biochem Parasitol. 2009 Nov;168(1):74-83. doi: 10.1016/j.molbiopara.2009.06.011. Epub 2009 Jul 8. PubMed PMID: 19591883; PubMed Central PMCID: PMC2741015.

11: Weichsel A, Montfort WR. Ligand-induced distortion of an active site in thymidylate synthase upon binding anticancer drug 1843U89. Nat Struct Biol. 1995 Dec;2(12):1095-101. PubMed PMID: 8846221.

12: Takimoto CH. Antifolates in clinical development. Semin Oncol. 1997 Oct;24(5 Suppl 18):S18-40-S18-51. Review. PubMed PMID: 9420020.

13: Duch DS, Banks S, Dev IK, Dickerson SH, Ferone R, Heath LS, Humphreys J, Knick V, Pendergast W, Singer S, et al. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res. 1993 Feb 15;53(4):810-8. PubMed PMID: 8428362.

14: Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML. Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors. Clin Cancer Res. 2008 Dec 1;14(23):7947-55. doi: 10.1158/1078-0432.CCR-08-0864. PubMed PMID: 19047127.

15: Beutel G, Glen H, Schöffski P, Chick J, Gill S, Cassidy J, Twelves C. Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors. Clin Cancer Res. 2005 Aug 1;11(15):5487-95. PubMed PMID: 16061865.

16: Laethem RM, Hannun YA, Jayadev S, Sexton CJ, Strum JC, Sundseth R, Smith GK. Increases in neutral, Mg2+-dependent and acidic, Mg2+-independent sphingomyelinase activities precede commitment to apoptosis and are not a consequence of caspase 3-like activity in Molt-4 cells in response to thymidylate synthase inhibition by GW1843. Blood. 1998 Jun 1;91(11):4350-60. PubMed PMID: 9596684.

17: Hunter JH, Gujjar R, Pang CK, Rathod PK. Kinetics and ligand-binding preferences of Mycobacterium tuberculosis thymidylate synthases, ThyA and ThyX. PLoS One. 2008 May 21;3(5):e2237. doi: 10.1371/journal.pone.0002237. PubMed PMID: 18493582; PubMed Central PMCID: PMC2386288.

18: Weichsel A, Montfort WR, Cieśla J, Maley F. Promotion of purine nucleotide binding to thymidylate synthase by a potent folate analogue inhibitor, 1843U89. Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3493-7. PubMed PMID: 7724588; PubMed Central PMCID: PMC42193.

19: Schmitz JC, Chen TM, Chu E. Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds. Cancer Res. 2004 Feb 15;64(4):1431-5. PubMed PMID: 14973067.

20: Banks SD, Waters KA, Barrett LL, Dickerson S, Pendergast W, Smith GK. Destruction of WiDr multicellular tumor spheroids with the novel thymidylate synthase inhibitor 1843U89 at physiological thymidine concentrations. Cancer Chemother Pharmacol. 1994;33(6):455-9. PubMed PMID: 8137455.